[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609371":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":18,"slug":7,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":21,"acronym":22,"eligibilityCriteria":23,"healthyVolunteers":19,"sex":24,"minAge":25,"maxAge":7,"enrollmentInfo":26,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Erica De Candia Prof.ssa Erica De Candia, MD","CONTACT","0630156329","erica.decandia@policlinicogemelli.it",{"type":15,"investigatorFullName":16,"investigatorTitle":17,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","De Candia Erica","Prof.ssa Erica De Candia","100609371",false,"NCT07213713","Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","EPOS","Inclusion Criteria:• age \\>18 years,\n\n* BMI \\>40 kg\u002Fm2\n* indication to primary or secondary thromboprophylaxis (Padua Score \\> 4), as clinical practice\n\nExclusion Criteria:• indication to full dose anticoagulant,\n\n* creatinine clearance \\\u003C30 mL\u002Fmin (based on Cockcroft-Gault equation using adjusted body weight),\n* pregnant women,\n* low platelet count (\\\u003C50.000\u002FmicroL or \\\u003C100.000\u002FmicroL plus additional risk factors for bleeding),\n* active bleeding,\n* active gastroduodenal ulcer,\n* severe bleeding diathesis,\n* recent\u002Fplanned\u002Femergency high bleeding-risk surgery\u002Fprocedure,\n* major trauma,\n* acute intracranial hemorrhage,\n* bleeding within the three months prior to admission,\n* known hypersensitivity to enoxaparin (e.g. pruritus, urticaria, anaphylactic\u002Fanaphylactoid reactions),\n* history of immune mediated heparin-induced thrombocytopenia (HIT),\n* severe uncontrolled hypertension,\n* diabetic or hemorrhagic retinopathy,\n* concurrent administration of subcutaneous drugs (i.e. insulin, GLP-1 receptor agonists, etc.).","ALL","18 Years",{"count":27,"type":28},80,"ESTIMATED","OBSERVATIONAL","To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity",[32,33],"Venous Thromboembolism","Obese Patients","NOT_YET_RECRUITING","2025-10-02",{"date":37,"type":38},"2025-10-09","ACTUAL",{"date":40,"type":28},"2025-10-01",{"date":42,"type":28},"2027-10-01",{"name":5,"class":6}]